MedTrace Logo

Pilot Study to Assess the Effects of AV608 on Irritable Bowel Syndrome

NCT00316550 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2008-02-25

No results posted yet for this study

Summary

The purpose of this study is to assess the effects of AV608, a neurokinin 1 (NK-1) antagonist, in subjects with Irritable Bowel Syndrome.

Conditions

  • Irritable Bowel Syndrome (IBS)

Interventions

DRUG

AV608

Sponsors & Collaborators

Principal Investigators

  • Joao Siffert, MD · Avera Pharmaceuticals, Inc.

  • Kirsten Tillisch, MD · UCLA Center for Neurovisceral Sciences and Women's Health

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-04-30
Primary Completion
2007-06-30
Completion
2007-09-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00316550 on ClinicalTrials.gov